Answers are grounded in this paper and cite their sources.
AIMS: Normoalbuminuric chronic kidney disease (NACKD) is increasingly prevalent in Type 2 diabetes (T2D). Here, we evaluated the kidney effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among T2D patients with baseline normoalbuminuria, taking into consideration their interim development of albuminuria, a risk factor for kidney function decline. MATERIALS AND METHODS: Using a real-world territory-wide electronic health record database, T2D patients with normoalbuminuria between January 2015 and December 2019 were identified. Incident kidney outcome was defined as a composite of sustained ≥ 40% decline in eGFR or end-stage kidney disease. Time-dependent Cox regression was used to evaluate the kidney effects of SGLT2i, modelling SGLT2i use and interim albuminuria status as time-varying covariates. Conditional logistic regression with time-dependent propensity score matching (TDPSM) was conducted to further evaluate the effects of SGLT2i in NACKD patients. RESULTS: Among the 226 434 T2D patients with baseline normoalbuminuria, over a median follow-up of 7.17 years (IQR: 5.50-8.17), use of SGLT2i (HR, 0.62, 95% CI, 0.57-0.66; p < 0.001) and interim development of albuminuria (HR, 1.90, 95% CI, 1.84-1.96; p < 0.001) were independently associated with incident kidney outcome, which remained statistically significant in subgroup and sensitivity analyses. In TDPSM, use of SGLT2i was associated with a lower risk of incident kidney outcome among NACKD patients (OR, 0.61, 95% CI, 0.49-0.77; p < 0.001). CONCLUSIONS: In T2D patients with normoalbuminuria, regardless of the presence of CKD, SGLT2i use was associated with a significantly lower risk of incident kidney outcome.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: